"The Street Podcast" Features Halberd's "Groundbreaking" Cancer Treatment Approach. Listen Now!

Rhea-AI Summary

Halberd Corporation has reported the successful application of its patented methodology for Cancer Antigen Eradication Treatment. CEO William Hartman and CTO Mitchell Felder discussed these groundbreaking achievements in an interview. The company's approach involves controlling cancer antigen levels, specifically CTLA-4, to enhance immune response without harmful side effects. This extracorporeal method aims to minimize drug-related fatalities, with over 100,000 deaths annually in the U.S. attributed to medication side effects. Halberd is progressing from in-vitro to in-vivo testing, seeking to advance its innovative treatment.

Positive

• Successful application of patented methodology for Cancer Antigen Eradication Treatment.
• Unique extracorporeal approach reduces or eliminates negative medication side effects.
• Progression from in-vitro to in-vivo testing indicates potential for human trials.
• Acquisition of exclusive worldwide rights to three granted patents enhances shareholder value.

Negative

• None.

CEO William Hartman and CTO Mitchell Felder report successful application of Halberd's patented methodology for Cancer Antigen Eradication Treatment.

JACKSON CENTER, PA / ACCESSWIRE / December 5, 2022 / Halberd Corporation's (OTC-PINK:HALB) Chairman, President and CEO William A. Hartman and Chief Technology Officer, Dr. Mitchell S. Felder, interviewed on "The Street Reports," discuss their groundbreaking accomplishments, successfully eradicating Cancer disease antigens".

Listen here: https://thestreetreports.com/the-street-podcast-features-halberds-groundbreaking-breast-cancer-antigen-eradication-listen-now-ceo-william-hartman-and-cto-mitchell-felder-discuss/

Dr. Mitchell S. Felder, Halberd's Chief Technology Officer and a board-certified attending neurologist stated, "The control of various cancer antigen levels is an indispensable step in eliminating and preventing cancer. The HALB approach is to control the exact concentration (to the picogram/ml level) of CTLA-4. The goal is to precisely lower CTLA-4 concentration to the exact, perfect level which would allow the cancer to be destroyed by the immune system, yet not cause any deleterious side effects. We have successfully applied this same technique of controlling antigen levels to other diseases with consistent success. So far, we have demonstrated this control in-vitro, and are moving to in-vivo testing in animals, and eventually in humans."

William A. Hartman, Chairman, President & CEO of Halberd Corporation, added, "What differentiates Halberd Corporation's patent protected approach from other applications is our extracorporeal (outside the body) method. We don't inject anything into the patient nor have them ingest drugs. Our process reduces or eliminates the negative side effects of medications. Over 100,000 deaths in the U.S. are the result of drug side-effects¹."

To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

¹https://health.usnews.com/health-news/patient-advice/articles/2016-09-27/the-danger-in-taking-prescribed-medications

About The Street Reports

The Street Reports discovering companies from "Wall Street 2 Bay Street" specializes in bringing relevant information on micro-cap, small-cap, and generally undervalued companies to the attention readers/listeners which maybe potential investors.

About Halberd Corporation.

Halberd Corporation (OTC-PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three granted patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of innovative, forward thinking development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/730015/The-Street-Podcast-Features-Halberds-Groundbreaking-Cancer-Treatment-Approach-Listen-Now

FAQ

What is Halberd Corporation's latest cancer treatment innovation?

Halberd Corporation's recent innovation is a patented methodology for Cancer Antigen Eradication Treatment, focusing on controlling cancer antigen levels.

Who discussed Halberd's cancer treatment on 'The Street Reports'?

CEO William Hartman and CTO Mitchell Felder discussed Halberd's cancer treatment on 'The Street Reports'.

How does Halberd's approach to cancer treatment differ from traditional methods?

Halberd's approach differs by using an extracorporeal method that avoids injecting substances into patients, thereby minimizing side effects.

What type of testing is Halberd moving towards following in-vitro success?

Halberd is moving towards in-vivo testing in animals and eventually aims for human trials.

What are the implications of Halberd's cancer treatment on medication side effects?

Halberd's treatment aims to reduce or eliminate the negative side effects of medications, which contribute to over 100,000 deaths annually in the U.S.